Mani Foroohar
Stock Analyst at Leerink Partners
(3.36)
# 1,063
Out of 5,046 analysts
171
Total ratings
52.13%
Success rate
2.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LXEO Lexeo Therapeutics | Maintains: Outperform | $9 → $20 | $10.01 | +99.80% | 6 | Oct 7, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Market Perform | $9 → $7 | $3.77 | +85.68% | 13 | Oct 3, 2025 | |
| MRNA Moderna | Maintains: Underperform | $18 → $15 | $27.16 | -44.77% | 18 | Aug 22, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | $45 → $10 | $24.01 | -58.35% | 2 | Jul 21, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $7 → $6 | $5.52 | +8.70% | 8 | Feb 28, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $11.50 | +134.78% | 9 | Jan 13, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $45 → $72 | $34.26 | +110.16% | 2 | Nov 12, 2024 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $17 | $4.16 | +308.65% | 1 | Nov 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $47 → $49 | $72.65 | -32.55% | 11 | Oct 17, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $47 → $46 | $62.64 | -26.56% | 15 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $22 | $9.04 | +143.36% | 6 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $53 → $62 | $74.30 | -16.55% | 15 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $16.36 | -20.54% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $21.04 | +37.83% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $4 | $5.34 | -25.09% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $12.77 | - | 10 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $7.15 | +333.57% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.44 | +386.11% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $42.39 | -5.64% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $12.62 | +565.61% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $3.08 | +127.27% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $25.01 | +207.88% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $144 → $143 | $456.04 | -68.64% | 11 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $4.81 | +24.74% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $63.99 | +18.77% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $2.42 | +1,304.96% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $20 | $4.30 | +365.12% | 6 | Jul 23, 2021 |
Lexeo Therapeutics
Oct 7, 2025
Maintains: Outperform
Price Target: $9 → $20
Current: $10.01
Upside: +99.80%
Rocket Pharmaceuticals
Oct 3, 2025
Maintains: Market Perform
Price Target: $9 → $7
Current: $3.77
Upside: +85.68%
Moderna
Aug 22, 2025
Maintains: Underperform
Price Target: $18 → $15
Current: $27.16
Upside: -44.77%
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Market Perform
Price Target: $45 → $10
Current: $24.01
Upside: -58.35%
Recursion Pharmaceuticals
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $5.52
Upside: +8.70%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $11.50
Upside: +134.78%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $34.26
Upside: +110.16%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $4.16
Upside: +308.65%
Mirum Pharmaceuticals
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $72.65
Upside: -32.55%
BridgeBio Pharma
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $46
Current: $62.64
Upside: -26.56%
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $9.04
Upside: +143.36%
Jul 24, 2024
Upgrades: Outperform
Price Target: $53 → $62
Current: $74.30
Upside: -16.55%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $16.36
Upside: -20.54%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $21.04
Upside: +37.83%
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $5.34
Upside: -25.09%
Mar 6, 2024
Upgrades: Outperform
Price Target: n/a
Current: $12.77
Upside: -
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $7.15
Upside: +333.57%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $1.44
Upside: +386.11%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $42.39
Upside: -5.64%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $12.62
Upside: +565.61%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $3.08
Upside: +127.27%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $25.01
Upside: +207.88%
Jan 23, 2023
Maintains: Market Perform
Price Target: $144 → $143
Current: $456.04
Upside: -68.64%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $4.81
Upside: +24.74%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $63.99
Upside: +18.77%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $2.42
Upside: +1,304.96%
Jul 23, 2021
Maintains: Market Perform
Price Target: $50 → $20
Current: $4.30
Upside: +365.12%